Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304239 · ClinicalTrials.gov registry record · Phase 3
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
A Phase 3 study of Actinic Keratosis, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
- 11
- Study locations
NCT00304239 is a Phase 3 study of Actinic Keratosis that has completed, run by Galderma R&D. The registered enrollment target is 131 participants, below the 181-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (28% lower). The trial reports 11 study locations across 5 states.
The verdict
NCT00304239, a Phase 3 study of Actinic Keratosis, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study was to compare the efficacy of Photodynamic Therapy (PDT) with methyl aminolevulinate (MAL) cream to PDT with vehicle cream, using the Light-emitting diode (LED) light source Aktilite CL128, in treatment of participants with multiple actinic keratosis (sun-damaged skin) on the face and/or scalp.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Metvix-PDT
- COMBINATION_PRODUCT Vehicle-PDT
Study Locations (11)
Other
- Hautklinik Heinrich Heine Universität - Düsseldorf
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main - Frankfurt
- Praxis Dr. Winfried Klövekorn - Gilching
- Klinik für Dermatologie und Venerologie Universitätsklinikum Schleswig-Holstein, Campus Lübeck - Lübeck
- Klinikum der Universität München, Klinikum und Poliklinik für Dermatologie und Allergologie - München
- Klinik und Poliklinik für Dermatologie, Klinikum der Universität Regensburg - Regensburg
- Praxis Dr. Klemm - Tutzing
Illinois
- Ashish C. Bhatia - Naperville
Kentucky
- Joseph Fowler - Louisville
Oregon
- Robert T. Matheson - Portland
Texas
- Steven A. Davis - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2006-03-13 |
| Est. Completion | 2007-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00304239
The ClinicalTrials.gov registry entry for NCT00304239 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (28% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which Metvix-PDT is the first listed.
NCT00304239 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Other, Illinois, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00304239 about?
NCT00304239 is a clinical study titled "Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp". The purpose of this study was to compare the efficacy of Photodynamic Therapy (PDT) with methyl aminolevulinate (MAL) cream to PDT with vehicle cream, using the Light-emitting diode (LED) light source Aktilite CL128, in treatment of participants with multiple actinic keratosis (sun-damaged skin) on ...
What is the current status of trial NCT00304239?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2006-03-13. Estimated completion is 2007-01-23.
What conditions does trial NCT00304239 study?
This clinical trial studies the following conditions: Actinic Keratosis.
What interventions are being tested in trial NCT00304239?
The interventions under investigation include: Metvix-PDT (COMBINATION_PRODUCT), Vehicle-PDT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT00304239?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00304239 being conducted?
This trial has 11 study locations across Illinois, Kentucky, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
ACTIVE NOT RECRUITING · Phase 3
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
COMPLETED · Phase 3
-
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
COMPLETED · Phase 3
-
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
COMPLETED · Phase 3
-
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.